{"id":820929,"date":"2025-03-03T16:35:52","date_gmt":"2025-03-03T21:35:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-to-participate-in-the-oppenheimer-35th-annual-healthcare-medtech-services-conference\/"},"modified":"2025-03-03T16:35:52","modified_gmt":"2025-03-03T21:35:52","slug":"nyxoah-to-participate-in-the-oppenheimer-35th-annual-healthcare-medtech-services-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-to-participate-in-the-oppenheimer-35th-annual-healthcare-medtech-services-conference\/","title":{"rendered":"Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference"},"content":{"rendered":"
\n

\n Nyxoah<\/strong>
\n to<\/strong>
\n Participate<\/strong>
\n in<\/strong>
\n the Oppenheimer<\/strong>
\n 35<\/strong>
\n
\n th<\/strong>
\n <\/sup>
\n Annual<\/strong>
\n Healthcare<\/strong>
\n MedTech<\/strong>
\n & Services Conference<\/strong>\n <\/p>\n

\n Mont-Saint-Guibert, Belgium \u2013 March 3, 2025, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH) <\/strong>(\u201cNyxoah\u201d or the \u201cCompany\u201d), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Oppenheimer 35th<\/sup> Annual Healthcare MedTech & Services Conference, which takes place March 17 \u2013 20, 2025.<\/p>\n

Olivier Taelman, Nyxoah\u2019s Chief Executive Officer, will deliver a corporate presentation on Monday, March 17, 2025, at 8:40am ET. A webcast<\/a> of the presentation will be available in the Events section of Nyxoah\u2019s Investor Relations website. The Company will be available for 1×1 meetings with institutional investors.<\/p>\n

Nyxoah\u2019s Investor Presentation can be accessed on the Shareholder<\/u>Information<\/u><\/a> section of the Company\u2019s
Investor Relations page.<\/p>\n

\n About<\/strong>
\n Nyxoah<\/strong>
\n
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio\u00ae, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.<\/p>\n

Following the successful completion of the BLAST OSA study, the Genio\u00ae system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors\u2019 therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.<\/p>\n

For more information, please visit http:\/\/www.nyxoah.com\/<\/u>.<\/a><\/p>\n

\n Caution <\/strong>\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Nyxoah<\/strong>
\n
John Landry, CFO
IR@nyxoah.com<\/u><\/a><\/p>\n

\n Attachment<\/strong>\n <\/p>\n